PERSONAL INFORMATION
Name：Huang Ailong
Gender：Male
CONTACT INFORMATION
Email：ahuang@cqmu.edu.cn
EDUCATION EXPERIENCE
1981.9-1985.6：BS, Biochemistry, Sichuan University
1985.9-1988.6：MS, Microbiology, Chengdu Institute of Biology, Chinese Academy of Sciences
WORKING EXPERIENCE
2018.4 to present President, Chongqing Medical University
2021.1 to present Director, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University
2004.09-2018.03 Vice-president, Chongqing Medical University
1999.07-2020.12 Vice director, Institute for Viral Hepatitis of Chongqing Medical University
RESEARCH INTERESTS
Professor Huang has been engaged in research on the pathogenesis and prevention of hepatitis B for a long time. Professor Huang has undertaken 4 state major projects in science and technology (major projects in infectious disease prevention and control), 2 state "863 Program" projects, and 4 projects of National Natural Science Foundations of China. In the past five years, the total scientific research funding has exceeded 60 million yuan.
In 2020, Professor Huang’s team successfully developed the world’s first chemiluminescence based SARS-CoV-2 antibody detection kit, and thus Professor Huang was granted the title as National Outstanding Individual in Combating COVID-19. A number of influential innovative research results have been achieved in hepatitis B virus replication regulation, drug resistance mechanism, antiviral drug screening and the pathogenesis of liver diseases, as well as the research and development of novel coronavirus infection diagnostic products and the pathogenic mechanism of infection. The team has also made a number of original achievements in the research of HBV replication regulation, drug resistance mechanism, antiviral drug screening, and the pathogenesis of associated liver diseases.
HONOR & AWARDS
1.Chief Scientist in National Major Project in Infectious Diseases
2. Distinguished Professor, Changjiang Scholar of the Ministry of Education
3.National Science Fund for Distinguished Young Scholars (Level-B)
4.The first group of National-level candidates in New Century Hundred Project
5.The National Outstanding Scientific and Technological Workers
6.Young and middle-aged experts with Outstanding Contributions to National Health and Family Planning
7. Recipient of special government allowances from the State Council
8.National Outstanding Individual in Combating COVID-19
PUBLICATIONS
1.Ailong Huang. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-848.
2.Ailong Huang. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-1204.
3.Ailong Huang. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2. Nat Med. 2020 Aug;26(8):1193-1195.
4.Ailong Huang. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol. 2021 Mar;74(3):522-534.
5.Ailong Huang. A Functional Variant in Ubiquitin Conjugating Enzyme E2 L3 Contributes to Hepatitis B Virus Infection and Maintains Covalently Closed Circular DNA Stability by Inducing Degradation of Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3A. Hepatology. 2019 May;69(5):1885-1902.
6.Ailong Huang. Identification of bis-benzylisoquinoline alkaloids as SARSCoV-2 entry inhibitors from a library of natural products. Signal Transduct Target Ther. 2021 Mar 23;6(1):131.
7.Ailong Huang. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat Commun. 2021 Mar 12;12(1):1618.
8.Ailong Huang. Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. J Clin Invest. 2021 Apr 15;131(8):144703.
9.Ailong Huang. GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone. EMBO J. 2019 Aug 1;38(15):e101964.
10.Ailong Huang. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cell Mol Immunol. 2021 Apr;18(4):1061-1063.
